Thrombus is a main cause of cardiac death. Therefore identifying which coronary artery plaque is vulnerable to rupture is a critical step for cardiac intervention to prevent future cardiac events. Systemic biochemical markers are used for predicting rupture of coronary plaque or identifying stenotic c oronary artery plaque(s) vulnerable to rupture.
Introduction
Of 241 cardiac deaths, 125 or 52% are caused by acute thrombi related to ruptures, erosions, and calcified nodules (1) . V ulnerable plaques have large lipid cores and thin fibrous caps, and are infiltrated by macrophages (2) . Angiographic definition of unstable plaque underlines the existence o f 50% o r more stenosis accompanied by at least 2 of the followings: intra luminal filling defect, ulcer in the plaque, irregular surface, and impaired blood flow (3) .
The association between Myeloperoxidase (MPO) and vulnerable plaque has been investigated recently (4) . Libby et al. showed co-localization of macrophages that expressed MPO and HOCl modified protein in plaque of a person who died of cardiac event (5) . MPO can be used as a predictor of plaque rupture (6) , even in Troponin T negative patients (7) .
Matrix Metalloproteinase-9 (MMP-9) can be used as predictor of cardiovascular mortality (8) . Detectable level of MMP-9 in the circulation is associated with left ventricular dimension and thickness of the wall in men (9) . Serum MMP-9 of stenotic patients is significantly higher than that of controls (10) . Plasma level of MMP-9 increases in infarction and unstable angina (11 (15) .
Circulating sPLA2-II i n blood has been demonstrated to be able to predict coronary events in initially healthy subjects and in patients with frank c oronary heart disease including acute coronary syndromes (16) . Lipoprotein that contains Apo-B and SPLA2-IIA can facilitate enzymatic hydrolysis of phospholipid lipoproteins through interaction with p roteoglycan in the artery. Further modification of lipoprotein causes aggregation and lipoprotein fusion within the plaque (17).
Methods PATIENTS Thirteen patients scheduled t o undergo stent p lacement in the coronary artery were involved in the study. Blood samples were taken from 12 x 2 (distal and proximal of the plaque) coronary artery stable plaques from 11 patients, and 2 x 2 (distal and proximal of the plaque) coronary unstable plaques from another two patients. Control blood samples were taken from each of the same patients from coronary artery that showed no stenosis (0% stenosis).
METHODS
Blood samples from coronary artery were taken using a microcatheter. Unstable plaque is defined according to the criteria of Goldstein. The level of CD40L and MMP-9 in the blood . 
Characteristics of t he s tudy subjects are shown i n Table 1 . Characteristics of the coronary artery p laques a re shown in Table 2 .
Levels of MMP-9, MPO, SPLA2 and CD40L of the distal and proximal coronary artery plaques are shown in Table  3 . Table 3 . MMP-9, MPO, SPLA2 and CD40L levels (mean + SD) in the distal and proximal coronary artery plaques between stable and unstable plaque * significance (p<0.05) Among t he b iomarkers used, MMP-9 showed a s ignificant i ncrease in unstable coronary artery p laque as compared with stable coronary artery plaque (p=0.024). On the other hand, SPLA2 showed a significant decrease in unstable coronary artery plaque compared with that in stable coronary artery plaque (p=0.015).
Biomarker

Control S
Assessment of each individual subject showed the average SPLA2 level of distal and proximal artery plaque decreased in 9 of 10 subjects with stable plaques as compared with the control, with an average decrease of 14 nstable coronary artery plaques absorbed SPLA2 from the vasculars in a greater amount than in stable plaques and non-plaques (control). In conclusion, MMP-9 and SPLA2 can be used as markers of stability of a plaque in coronary artery towards rupture vulnerability.
Conclusion
